JP2022502492A5 - - Google Patents
Info
- Publication number
- JP2022502492A5 JP2022502492A5 JP2021540380A JP2021540380A JP2022502492A5 JP 2022502492 A5 JP2022502492 A5 JP 2022502492A5 JP 2021540380 A JP2021540380 A JP 2021540380A JP 2021540380 A JP2021540380 A JP 2021540380A JP 2022502492 A5 JP2022502492 A5 JP 2022502492A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- thiamine
- composition according
- patient
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024125670A JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736369P | 2018-09-25 | 2018-09-25 | |
| US62/736,369 | 2018-09-25 | ||
| US201862783076P | 2018-12-20 | 2018-12-20 | |
| US62/783,076 | 2018-12-20 | ||
| PCT/US2019/052608 WO2020068755A1 (en) | 2018-09-25 | 2019-09-24 | Methods of treating myeloproliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125670A Division JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502492A JP2022502492A (ja) | 2022-01-11 |
| JP2022502492A5 true JP2022502492A5 (https=) | 2022-10-03 |
Family
ID=69950867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540380A Pending JP2022502492A (ja) | 2018-09-25 | 2019-09-24 | 骨髄増殖性疾患の治療法 |
| JP2024125670A Pending JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125670A Pending JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220031699A1 (https=) |
| EP (1) | EP3856169A4 (https=) |
| JP (2) | JP2022502492A (https=) |
| KR (2) | KR20210102192A (https=) |
| CN (1) | CN113286584A (https=) |
| AU (1) | AU2019346521B2 (https=) |
| BR (1) | BR112021005518A2 (https=) |
| CL (1) | CL2021000744A1 (https=) |
| IL (1) | IL281736A (https=) |
| MA (1) | MA53741A (https=) |
| MX (2) | MX2021003450A (https=) |
| MY (1) | MY209349A (https=) |
| SG (1) | SG11202103019WA (https=) |
| WO (1) | WO2020068755A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| KR20250134004A (ko) * | 2018-09-25 | 2025-09-09 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| US20240058336A1 (en) | 2020-12-16 | 2024-02-22 | Impact Biomedicines, Inc. | Dosing of fedratinib |
| MX2023009858A (es) | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| WO2023044297A1 (en) | 2021-09-14 | 2023-03-23 | Impact Biomedicines, Inc. | Fedratinib for treating myeloproliferative disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| US20090093009A1 (en) * | 2007-10-09 | 2009-04-09 | Sum Chan | Mass spectrometry method for measuring thiamine in body fluid |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US20130102624A1 (en) * | 2011-05-19 | 2013-04-25 | John V. Schloss | Early detection of thiamine deficiency |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| EP3099677A4 (en) * | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| CN108348578B (zh) * | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| KR20250134004A (ko) | 2018-09-25 | 2025-09-09 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
| FR3092581A1 (fr) | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
-
2019
- 2019-09-24 BR BR112021005518-5A patent/BR112021005518A2/pt unknown
- 2019-09-24 US US17/279,765 patent/US20220031699A1/en not_active Abandoned
- 2019-09-24 EP EP19866319.7A patent/EP3856169A4/en active Pending
- 2019-09-24 JP JP2021540380A patent/JP2022502492A/ja active Pending
- 2019-09-24 KR KR1020217012234A patent/KR20210102192A/ko not_active Ceased
- 2019-09-24 WO PCT/US2019/052608 patent/WO2020068755A1/en not_active Ceased
- 2019-09-24 MX MX2021003450A patent/MX2021003450A/es unknown
- 2019-09-24 MA MA053741A patent/MA53741A/fr unknown
- 2019-09-24 CN CN201980070403.4A patent/CN113286584A/zh active Pending
- 2019-09-24 SG SG11202103019WA patent/SG11202103019WA/en unknown
- 2019-09-24 KR KR1020257037570A patent/KR20250164332A/ko active Pending
- 2019-09-24 MY MYPI2021001641A patent/MY209349A/en unknown
- 2019-09-24 AU AU2019346521A patent/AU2019346521B2/en active Active
-
2021
- 2021-03-22 IL IL281736A patent/IL281736A/en unknown
- 2021-03-24 MX MX2023013844A patent/MX2023013844A/es unknown
- 2021-03-25 CL CL2021000744A patent/CL2021000744A1/es unknown
- 2021-12-23 US US17/560,373 patent/US11400092B2/en active Active
-
2024
- 2024-08-01 JP JP2024125670A patent/JP2024161416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502492A5 (https=) | ||
| JP6984024B2 (ja) | Ｃｙｐ３ａ４基質薬物による処置方法 | |
| JP2609968B2 (ja) | グリシン／ｎｍｄａ受容体複合体の機能性拮抗剤による情緒障害の治療 | |
| CN101563086B (zh) | 睾酮和5-ht1a激动剂在治疗性功能障碍中的应用 | |
| KR20250136946A (ko) | 트라디피턴트에 의한 치료 방법 | |
| JP2021526138A5 (https=) | ||
| EP3010505A1 (en) | Pharmaceutical combinations | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| US20060173074A1 (en) | Treatment of restless legs syndrome | |
| JP2021046394A5 (https=) | ||
| US20250170109A1 (en) | Method of treating malignant tumor by azabicyclic compound | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| CN104039148A (zh) | 组合als疗法 | |
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| WO2007000764A2 (en) | Compositions and methods for enhancement of sexual function | |
| CN101610760A (zh) | 恶病质的治疗 | |
| US20120071464A1 (en) | Method of treatment of obsessive compulsive disorder with ondansetron | |
| PL211211B1 (pl) | Zestawienie propionylo-L-karnityny z sildenafilem, kompozycja farmaceutyczna je zawierająca i jego zastosowanie | |
| JP2006508118A5 (https=) | ||
| JP6328856B2 (ja) | 収縮力低下随伴性排尿筋過活動改善剤 | |
| US20170266132A1 (en) | Method for treating hyperhidrosis | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JP6420923B1 (ja) | 医薬 | |
| Sano | Finding the Balance: Review of Pharmacological Management of Orthostatic Hypotension in Patients With Parkinson's Disease | |
| AU2013301125B2 (en) | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction |